Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: Dietman who wrote (50177)	2/8/2019 2:47:22 PM
From: bobbseytwins2001	14 Recommendations Recommended By bnutman diaperdaddy Dietman dorightbythem fatboy14 and 9 more members Read Replies (3) \| Respond to of 63276

We have heard all the discussions, ranting, and analyst updates and we have learned virtually nothing new. IMMU says they know the issues in the CRL amplified by the EIR and think they have taken care of what was mentioned. The FDA says the plant needs to be reinspected, but does not explain why it was not done before the PDUFA date, and/or why they apparently did not share the non inspection situation with IMMU. Regardless, it does not seem at all reasonable to us that it takes two months, six months or longer for the FDA to reinspect a plant that is producing a breakthrough product for a disease where the victims have no options. In addition the company says they are interacting with said FDA almost daily. What are we missing?